Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757859 | 0.76 | — | — | |
| SCHEMBL1420960 | 0.68 | TSHR (0.42) | MAOAMAOB | |
| SCHEMBL29657670 | 0.68 | TSHR (0.42) | MAOAMAOB | |
| SCHEMBL8657021 | 0.67 | MAOA (0.34) | MAOAMAOB | |
| SCHEMBL8469727 | 0.66 | TDP1 (0.46) | KMT2AGAA | |
| SCHEMBL8366509 | 0.66 | MAOA (0.33) | MAOAMAOB | |
| SCHEMBL1871104 | 0.65 | MAOA (0.46) | MAOAMAOBABCG2ITGB2ICAM1 | |
| SCHEMBL16862173 | 0.65 | MAOA (0.46) | MAOAMAOBOXTRGAANPSR1 | |
| SCHEMBL574743 | 0.65 | MAOA (0.41) | MAOAMAOBABCG2ITGB2ICAM1 | |
| SCHEMBL3074959 | 0.64 | MAOA (0.50) | MAOAMAOBABCG2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5679675-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | claimed |
| CN-116669453-A | Light emitting device, electronic device comprising the same, and mixture | 三星电子株式会社 | 2023-08-29 | — | — | CN | disclosed |
| CN-114249749-A | Conversion method of marbofloxacin formate | 天象生物药业邢台有限责任公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2019-09-26 | — | — | US | disclosed |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2220176-B1 | SOL-GEL COATING COMPOSITIONS AND THEIR PROCESS OF PREPARATION | DUBLIN INSTITUTE OF TECH INTELLECTUAL PROPERTY LTD (IE) | 2018-09-19 | — | — | EP | disclosed |
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2018-02-01 | — | — | US | disclosed |
| US-5679675-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5679675-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| WO-1997012613-A1 | METHOD FOR TREATING AND PREVENTING INFLAMMATION AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-04-10 | — | — | WO | disclosed |
| CN-1114652-A | 8-amino-pyrido(1,2,3-D,E)(1,3,4) benzoxadiazine derivatives | BAYER AG (DE) | 1996-01-10 | — | — | CN | disclosed |
| EP-0682030-A1 | 8-Amino-10(azabicycloalkyl)-pyrido[1,2,3-d,e] [1,3,4] benzoxadiazine derivatives, process for their preparation and antibacterial agents containing them | BAYER AG (DE) | 1995-11-15 | — | — | EP | disclosed |
| EP-0564193-A1 | Heteroannulation process | ELI LILLY AND COMPANY (US) | 1993-10-06 | — | — | EP | disclosed |
| EP-0219852-B1 | CHARTREUSIN DERIVATIVES, SALTS THEREOF, ANTITUMOROUS COMPOSITIONS CONTAINING THE SAME, AND PROCESSES FOR PRODUCING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5064945-A | Antitumor Agents | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1991-11-12 | — | — | US | disclosed |
| US-4927919-A | ANTITUMOR AGENTS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0219852-A2 | Chartreusin derivatives, salts thereof, antitumorous compositions containing the same, and processes for producing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | MAOA 1541/4885MAOB 1282/4885ABCG2 676/4885 |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | MAOA 1541/4885MAOB 1282/4885ABCG2 676/4885 |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | MAOA 1541/4885MAOB 1282/4885ABCG2 676/4885 |
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | MAOA 1599/4885MAOB 1360/4885ABCG2 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.